Biomarin Pharmaceutical Inc (BMRN)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $12.60B
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: October 26, 2026
Profit #948 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 35.0% | 42.1% | 45.0% | 50.7% |
Growth #670 of 1484 companies
Payout #1117 of 1484 companies
Safety #158 of 1484 companies
Price #912 of 1484 companies
